Fesoterodine (Toviaz): new option for overactive bladder

Fesoterodine, the prodrug of the active metabolite of tolterodine, has been launched in two strengths for the treatment of overactive bladder. In our New products review Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Dr Adrian Wagg comments on its place in treatment. Copyright © 2008 Wiley Interface Ltd